(19)
(11) EP 1 230 925 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.03.2006 Bulletin 2006/09

(45) Mention of the grant of the patent:
31.08.2005 Bulletin 2005/35

(21) Application number: 00971704.2

(22) Date of filing: 01.11.2000
(51) International Patent Classification (IPC): 
A61K 31/7072(2000.01)
A61K 31/506(2000.01)
 A61K 31/513(2000.01)
A61P 31/18(2000.01)
(86) International application number:
PCT/JP2000/007676
(87) International publication number:
WO 2001/034162 (17.05.2001 Gazette 2001/20)

(54)

USE OF A TRIFLURIDINE DERIVATIVE ALONE OR COMBINED WITH A THYMIDINE PHOSPHORYLASE INHIBITOR FOR THE TREATMENT OF HIV

VERWENDUNG VON EINEM TRIFLURIDIN DERIVAT ALLEIN ODER IN KOMBINATION MIT EINEM THYMIDIN-PHOSPHORYLASE-HEMMER ZUR BEHANDLUNG VON HIV

UTILISATION D'UN DERIVE DE TRIFLURIDINE SEUL OU EN ASSOCIATION AVEC UN INHIBITEUR DE LA THYMIDINE PHOSPHORYLASE POUR LE TRAITEMENT DU VIH

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 05.11.1999 JP 31567099

(43) Date of publication of application:
14.08.2002 Bulletin 2002/33

(73) Proprietor: TAIHO PHARMACEUTICAL CO., LTD.
Chiyoda-ku Tokyo 101-0054 (JP)

(72) Inventors:
  • HOSHINO, Hiroo
    Maebashi-shi, Gunma 371-0027 (JP)
  • KITAZATO, Kenji
    Tokushima-shi, Tokushima 770-0003 (JP)
  • FUKUSHIMA, Masakazu
    Hanno-shi, Saitama 357-0032 (JP)

(74) Representative: Müller-Boré & Partner Patentanwälte 
Grafinger Strasse 2
81671 München
81671 München (DE)


(56) References cited: : 
EP-A- 1 080 726
EP-A1- 0 763 529
US-A- 4 886 877
 EP-A1- 0 289 229
WO-A1-87/04929
   
  • SUZUKI N ET AL: "Invention of a novel antitumor agent, TAS-102: (2) Antitumor activities of 5-trifluorothymidine combined with a new inhibitor of thymidine phosphorylase" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 38, no. 0, 1997, page 101 XP001180068 Eighty-eighth Annual Meeting of the American Association for Cancer Research;San Diego, California, USA; April 12-16, 1997, 1997 ISSN: 0197-016X
  • DATABASE CAPLUS [Online] AMERICAN CHEMICAL SOCIETY (ACS), (COLUMBUS, OHIO, USA). KESSLER H.A. ET AL.: 'Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172)', XP002936343 Retrieved from STN Database accession no. DN. 125:75491 & J. AQUIRED IMMUNE DEFIC. SYNDR. HUM. RETROVIROL. vol. 12, no. 2, 1996, pages 147 - 152
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).